Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

It takes a lot of computing power to run an AI product — and as the tech industry races to tap the power of AI models, there’s a parallel race underway to build the infrastructure that will power them ...